[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100554449":3},{"organization":4,"armGroups":7,"interventions":26,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":67,"collaborators":18,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":18,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":18,"enrollmentInfo":78,"targetDuration":18,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":18,"overallStatus":49,"whyStopped":18,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Tongji Hospital","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"TMP\u002FSMX (with PJP high risk)","EXPERIMENTAL","AIIRD patients who have PJP high risk and receive prophylactic Trimethoprim\u002F Sulfamethoxazole (TMP\u002FSMZ) treatment; Drug intervention: Patients receive Trimethoprim\u002FSulfamethoxazole (TMP\u002FSMX) 480 mg p.o. every day as PJP Prophylaxis.",[13],"Drug: Trimethoprim\u002FSulfamethoxazole",{"label":15,"type":16,"description":17,"interventionNames":18},"no TMP\u002FSMX (with PJP high risk)","NO_INTERVENTION","AIIRD patients who have PJP high risk and do not receive prophylactic Trimethoprim\u002F Sulfamethoxazole (TMP\u002FSMZ) treatment.",null,{"label":20,"type":10,"description":21,"interventionNames":22},"TMP\u002FSMX (with PJP low-risk)","AIIRD patients who have PJP low risk and receive prophylactic Trimethoprim\u002F Sulfamethoxazole (TMP\u002FSMZ) treatment; Drug intervention: Patients receive Trimethoprim\u002FSulfamethoxazole (TMP\u002FSMX) 480 mg p.o. every day as PJP Prophylaxis.",[13],{"label":24,"type":16,"description":25,"interventionNames":18},"no TMP\u002FSMX (with PJP low-risk)","AIIRD patients who have PJP low risk and do not receive prophylactic Trimethoprim\u002F Sulfamethoxazole (TMP\u002FSMZ) treatment.",[27],{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"DRUG","Trimethoprim\u002FSulfamethoxazole","Patients received Trimethoprim\u002FSulfamethoxazole (TMP\u002FSMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).",[9,20],[33],"TMP\u002FSMX",[35],{"name":36,"affiliation":5,"role":37},"Lingli Dong","PRINCIPAL_INVESTIGATOR",[39,43],{"name":36,"role":40,"phone":41,"phoneExt":18,"email":42},"CONTACT","02783665519","tjhdongll@163.com",{"name":44,"role":40,"phone":45,"phoneExt":18,"email":46},"Shaozhe Cai","02783665518","540361903@qq.com",[48],{"facility":5,"status":49,"city":50,"state":51,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Wuhan","Hubei","43003","China","CN",{"type":56,"coordinates":57},"Point",[58,59],114.26667,30.58333,{"lat":59,"lon":58},[62,65],{"name":63,"role":40,"phone":64,"phoneExt":18,"email":42},"Dong Lingli, MD","+862783665519",{"name":66,"role":40,"phone":64,"phoneExt":18,"email":46},"Cai Shaozhe, MD",{"type":37,"investigatorFullName":36,"investigatorTitle":68,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Professor","100554449","phase-4-efficacy-and-safety-of-prophylactic-treatment-for-pneumocystis-jirovecii-pneumonia-in-patients-with-autoimmune-inflammatory-rheumatic-disease-100554449",false,"NCT06499233","Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia in Patients With Autoimmune Inflammatory Rheumatic Disease","Efficacy and Safety of Prophylactic Treatment for Pneumocystis Jirovecii Pneumonia (PJP) in Patients With Autoimmune Inflammatory Rheumatic Disease (AIIRD)","Inclusion Criteria:\n\n1. The patient was diagnosed with AIIRD according to the International Classification of Diseases and had received steroids or immunosuppressive therapy;\n2. The patient had not received standard PJP treatment before enrollment, including the first-line treatment drug TMP\u002FSMZ, or other second-line treatment drugs (including Pentamidine, Atorvastatin, Caspofungin, etc.);\n3. The patient was at least 18 years old at the time of enrollment;\n\nExclusion Criteria:\n\n1. Serious health problems or diseases, including (but not limited to) the following: severe liver damage (ALT, AST elevated above normal value by more than 5 times), severe renal insufficiency (GFR \\\u003C 30mL\u002Fmin or Scr \\> 445umol\u002FL), severe myelosuppression (Hb \\\u003C 65g\u002FL, PLT \\\u003C 25×10\\^9\u002FL or neutrophils \\\u003C 0.5×10\\^9\u002FL);\n2. Screening test indicates infection with human immunodeficiency virus (HIV), history of lymphomatous hyperplasia of the lymphatic tissue or any malignant tumor of any organ system within the past 5 years, or history of organ transplantation;\n3. Participants with a history of allergy to sulfonamide drugs, megaloblastic anemia due to folate deficiency;\n4. Pregnant and lactating women;\n5. Any medical or psychological condition that the investigator believes would interfere with the participant's ability to comply with the protocol or complete the study;\n6. Patients who refuse to comply with the requirements of this study and complete the study;\n7. Any other situation that the investigator considers unsuitable for participation in the study (for reasons including but not limited to management reasons).","ALL","18 Years",{"count":79,"type":80},800,"ESTIMATED","INTERVENTIONAL",[83],"PHASE4","This is an open-labeled, prospective clinical study aims at collecting and analyzing baseline characteristics of autoimmune inflammatory rheumatic disease (AIIRD) patients receiving sulfanilamide for preventive purposes, as well as subsequent follow-up data, in order to assess the efficacy and safety of the medication. Additionally, through a stratified analysis of risk factors, the investigators aim to identify the AIIRD population that would benefit most from preventive medication based on a favorable benefit-risk ratio.",[86,87,88,89,90],"Pneumonia, Pneumocystis","Autoimmune Inflammatory Rheumatic Disease","Autoimmune Diseases","Connective Tissue Disease","Prevention","2024-09-27",{"date":93,"type":94},"2024-10-01","ACTUAL",{"date":96,"type":94},"2024-07-20",{"date":98,"type":80},"2026-12-31",{"name":5,"class":6},1]